Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made...
- epNECs are aggressive malignancies with poor prognosis and no approved therapies, representing significant unmet medical need - Preliminary...
Zai Lab (NASDAQ:ZLAB) reported a year-over-year decline in first-quarter 2026 product revenue as pressure on ZEJULA weighed on results, while management emphasized progress across its global oncology and...
– Total revenues of $99.6 million for the first quarter of 2026, reflecting anticipated first-quarter dynamics, including certain competitive impacts for ZEJULA and pricing adjustment related...
Barchart Research What to Expect from ZLAB Earnings ZLAB Generated May 6, 2026 Current Price $21.01 EPS Estimate $$-0.58 Consensus Rating Moderate Buy Average Move 6.22% Zai Lab: Can China Commercial Momentum...
- Company to host conference call and webcast on May 7, 2026, at 8:00 a.m. ET (8:00 p.m. HKT)
-Efficacy and safety data shared at IMMUNOLOGY2026 reinforce potential of ZL-1503 as a first-in-class treatment for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases ...
 Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases;...
- Collaboration with Amgen to explore the clinical potential of Zai Lab’s DLL3-targeting ADC, zocilurtatug pelitecan, in combination with Amgen’s IMDELLTRA ® ...
- Zoci data show intracranial response in small-cell lung cancer (SCLC) with brain metastases, as well as activity in other neuroendocrine carcinomas - ...